Herpes simplex virus latency and nucleoside analogues

Antiviral Research

Volumn 41, Issue 3, 1999, Pages 85-100

  Efstathiou, Stacey ^a   Field, Hugh J ^b   Griffiths, Paul D ^c   Kern, Earl R ^d   Sacks, Stephen L ^e   Sawtell, Nancy M ^f   Stanberry, Lawrence R ^f  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Acyclovir; Famciclovir; Herpes simplex virus; Latency; Nucleosides analogues; Valaciclovir

Indexed keywords

ACICLOVIR; FAMCICLOVIR; NUCLEOSIDE ANALOG; PENCICLOVIR; THYMIDINE KINASE; VALACICLOVIR; VIRUS DNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; GENITAL HERPES; GUINEA PIG; HERPES; HERPES SIMPLEX; HERPES SIMPLEX VIRUS; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PATHOGENESIS; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; VIRUS LATENCY; VIRUS REACTIVATION; VIRUS REPLICATION;

ANIMALIA; CAVIA PORCELLUS; DNA VIRUSES; HERPES; HUMAN HERPESVIRUS 1; HUMAN HERPESVIRUS 2; SIMPLEXVIRUS; SUS SCROFA;

EID: 0033014863     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(99)00003-0     Document Type: Article

References (63)

1. Bernstein D.I., Stanberry L.R., Harrison C.J., Kappes J.C., Myers M.G. Antibody response, recurrence patterns and subsequent herpes simplex virus type 2 (HSV-2) re-infection following initial HSV-2 infection of guinea-pigs: effects of acyclovir. J. Gen. Virol. 67:1986;1601-1612.
2. Blyth W.A., Harbour D.A., Hill T.J. Effect of acyclovir on recurrence of herpes simplex skin lesions in mice. J. Gen. Virol. 48:1980;417-419.
3. Block T.M., Hill J.M. The latency associated transcripts (LAT) of herpes simplex virus: still no end in sight. J. Neurovirol. 3:1997;313-321.
4. Bryson Y., Dillon M., Lovett M., Bernstein D., Garratty E., Sayre J. Treatment of first episode genital HSV with oral acyclovir: long-term follow-up of recurrences. A preliminary report. Scand. J. Infect. Dis. Suppl. 47:1985;70-75.
5. Corey L., Fife K.H., Benedetti J.K., Winter C.A., Fahnlander A., Connor J.D., Hintz M.A., Holmes K.K. Intravenous acyclovir for the treatment of primary genital herpes. Ann. Intern. Med. 98:1983;914-921.
6. Corey L., Benedetti J.K., Critchlow C., Mertz G., Douglas J., Fife K.H., Fahnlander A., Remington M.L., Winter C.A., Dragavon J. Treatment of primary first-episode genital herpes simplex virus infections with acyclovir: results of topical intravenous and oral therapy. J. Antimicrob. Chemother. (suppl. B). 12:1983;79-88.
7. Corey L., Mindel A., Fife K.H., Sutherland S., Benedetti J., Adler M.W. Risk of recurrence after treatment of first-episode genital herpes with intravenous acyclovir. Sex. Transm. Dis. 12:1985;215-218.
8. Deatly C., Spivak J.G., Lavi E., Fraser N.W. RNA from and immediate early region of the type 1 herpes simplex virus genome is present in the trigeminal ganglia of latently infected mice. Proc. Natl. Acad. Sci. USA. 84:1987;3204-3208.
9. Deshmane S.L., Fraser N.W. During latency, herpes simplex virus type 1 DNA is associated with nucleosomes in a chromatin structure. J. Virol. 63:1989;2179-2190.
10. Ecob-Prince M.S., Preston C.M., Rixon F.J., Hassan K., Kennedy P.G. Neurons containing latency-associated transcripts are numerous and widespread in dorsal root ganglia following footpad inoculation of mice with herpes simplex virus type 1 mutant in1814. J. Gen. Virol. 74:1993;985-994.
11. Efstathiou S., Minson A.C., Field H.J., Anderson J.R., Wildy P. Detection of herpes simplex virus-specific DNA sequences in latently infected mice and in humans. J. Virol. 57:1986;446-455.
12. Efstathiou S., Kemp S., Darby G., Minson A.C. The role of herpes simplex virus type 1 thymidine kinase in pathogenesis. J. Gen. Virol. 70:1989;869-879.
13. Field H.J., Bell S.E., Elion G.B., Nash A.A., Wildy P. Effect of acycloguanosine treatment on acute and latent herpes simplex infections in mice. Antimicrob. Agents Chemother. 15:1979;554-561.
14. Field H.J., DeClerq E. Effects of oral treatment with acyclovir and bromovinyldeoxyuridine on the establishment and maintenance of latent herpes simplex virus infection in mice. J. Gen. Virol. 56:1981;259-265.
15. Field H.J., Tewari D., Sutton D., Thackray A.M. Comparison of efficacies of famciclovir and valaciclovir against herpes simplex virus type 1 in a murine immunosuppresion model. Antimicrob. Agents Chemother. 39:1995;1114-1119.
16. Field H.J., Efstathiou S., Thackray A.M. HSV latency detected in neurons by means of the β-gal reporter gene in ganglia from mice treated with famciclovir or valaciclovir (abstract). Antiviral Res. 37(14):1998;A43.
17. Fife K.H., Crumpacker C.S., Mertz G.J., Hill E.L., Boone G.S. Recurrence and resistance patterns of herpes simplex virus following cessation of>or=6 years of chronic suppression with acyclovir. Acyclovir Study Group. J. Infect. Dis. 169:1994;1338-1341.
18. Fraser N.W., Block T.M., Spivack J.G. The latency associated transcripts of herpes simplex virus: RNA in search of a function. Virology. 191:1992;1-8.
19. Harbour D.A., Hill T.J., Blyth W.A. Recurrent herpes simplex in the mouse: inflammation in the skin and activation of virus in the ganglia following peripheral stimulation. J. Gen. Virol. 64:1983;1491-1498.
20. Hill T.J., Field H.J., Blyth W.A. Acute and recurrent infection with herpes simplex in the mouse: a model for studying latency and recurrent disease. J. Gen. Virol. 28:1975;341-353.
21. Hill J.M., Maggioncalda J.B., Garza H.H., Su Y.H., Fraser N.H., Block T.M. In vivo epinephrine reactivation of ocular herpes simplex virus type 1 in the rabbit is correlated to a 370-base-pair region located between the promoter and the 5′ end of the 2.0 kilobase latency-associated transcript. J. Virol. 70:1996;7270-7274.
22. Katz J.P., Bodin E.T., Coen D.M. Quantitative polymerase chain reaction analysis of herpes simplex virus DNA in ganglia of mice infected with replication-incompetent mutants. J. Virol. 64:1990;4288-4295.
23. Kinghorn G.R., Abbeywickreme I., Jeavons M., Rowland M., Barton I., Al-Hasani G., Potter C.W., Hickmott E. Efficacy of oral treatment with acyclovir and co-trimoxazole in first episode genital herpes. Genitourin. Med. 62:1986;33-37.
24. Klein R.J., Friedman-Klein A.E., DeStefano E. Latent herpes simplex infections in sensory ganglia of hairless mice prevented by acycloguanosine. Antimicrob. Agents Chemother. 15:1979;723-729.
25. Krause P.R., Stanberry L.R., Bourne N., Connelly B., Kurawadwala J.F., Patel A., Straus S.E. Expression of the herpes simplex virus type 2 latency-associated transcript enhances spontaneous reactivation of genital herpes in latently infected guinea pigs. J. Exp. Med. 181:1995;297-306.
26. Latchman D. S. Regulation of viral and cellular gene expression in sensory neurons. Gene Ther. 1(Suppl. 1):1994;S25-S27.
27. Leib D.A., Bogard C.L., Kosz-Vnenchak M., Hicks K.A., Coen D.M., Knipe D.M., Schaffer P.A. A deletion mutant of the latency-associated transcript of herpes simplex virus type 1 reactivates from the latent state with reduced frequency. J. Virol. 63:1989;2893-2900.
28. Martin J.A., Thomas G.J., Merrett J. et al. The design, synthesis and properties of highly potent and selective inhibitors of herpes simplex virus types 1 and 2 thymidine kinase. Antivir. Chem. Chemother. 9:1998;1-8.
29. Mellerick D.M., Fraser N.W. Physical state of the latent herpes simplex virus genome in a mouse model system: evidence suggesting an episomal state. Virology. 158:1987;265-275.
30. Mindel A., Adler M.W., Sutherland S., Fiddian A.P. Intravenous acyclovir treatment for primary genital herpes. Lancet. 1:1982;697-700.
31. Openshaw H. Latency of herpes simplex virus in ocular tissue of mice. Infect. Immun. 39:1983;960-962.
32. Park N.H., Pavan-Langston D., McLean S.L. Acyclovir in oral and ganglionic herpes simplex virus infections. J. Infect. Dis. 140:1979;802-806.
33. Pavan-Langstan D., Park N.H., Hettinger M. Ganglionic herpes simplex and systemic acyclovir. Arch. Opthalmol. 99:1981;1417-1419.
34. Peacock J.E., Kaplowitz L.G., Sparling P.F., Durack D.T., Gnann J.W. Jr., Whitley R.J., Lovett M., Bryson Y.J., Klein R.J., Friedman Kein A.E. et al. Intravenous acyclovir therapy of first episodes of genital herpes: a multicenter double-blind, placebo-controlled trial. Am. J. Med. 85:1988;301-306.
35. Perng G.C., Dunkel E.C., Geary P.A., Slanina S.M., Ghiasi H., Kaiwar R., Nesburn A.B., Wchsler S.L. The latency-associated transcript genes of herpes simplex virus type 1 (HSV-1) is required for efficient in vivo spontaneous reactivation of HSV-1 from latency. J. Virol. 68:1994;8045-8055.
36. Rock D.L., Fraser N.W. Detection of HSV-1 genome in central nervous system of latently infected mice. Nature. 302:1983;523-525.
37. Rock D.L., Fraser N.W. Latent herpes simplex virus type 1 DNA contains two copies of the virion DNA joint region. J. Virol. 55:1985;849-852.
38. Roizman B., Sears A.E. An inquiry into the mechanism of herpes simplex virus latency. Ann. Rev. Microbiol. 41:1987;543-571.
39. Roizman B., Sears A.E. Herpes simplex viruses and their replication. Fields B.N., Knipe D.M., Howley P.M. et al. Fields Virology. 1996;Lippincott-Raven, Philadelphia.
40. Sawtell N.M., Thompson R.L. Rapid in vivo reactivation of herpes simplex virus in latently infected murine ganglionic neurons after transient hyperthermia. J. Virol. 66:1992;2150-2156.
41. Sawtell N.M. Comprehensive quantification of herpes simplex virus latency at the single cell level. J. Virol. 71:1997;5423-5431.
42. Sawtell N.M. The probability of in vivo reactivation of herpes simplex virus type 1 increases with the number of latently infected neurons in the ganglia. J Virol. 72:1998;6888-6892.
43. Sawtell N.M., Poon D.K., Tansky C.S., Thompson R.L. The latent herpes simplex virus type 1 genome copy number in individual neurons is virus strain specific and correlates with reactivation. J. Virol. 72:1998;5343-5350.
44. Sears A.E., Roizman B. Amplification by host cell factors of a sequence contained within the herpes simplex virus 1 genome. Proc. Natl. Acad. Sci. 87:1990;9441-9444.
45. Sears A.E., Hukkanen V., Labow M.A., Levine A.J., Roizman B. Expression of the herpes simplex virus 1 alpha transducing factor (VP16) does not induce reactivation of latent virus or prevent the establishment of latency in mice. J. Virol. 65:1991;2929-2935.
46. Shimeld C., Hill T.J., Blyth W.A., Easty D.L. Reactivation of latent infection and induction of recurrent herpetic eye disease in mice. J. Gen. Virol. 71:1990;397-404.
47. Simmons A., Slobedman B., Speck P., Arthur J., Efstathiou S. Two patterns of persistence of herpes simplex virus DNA sequences in the nervous systems of latently infected mice. J. Gen. Virol. 73:1992;1287-1291.
48. Slobedman B., Efstathiou S., Simmons A. Quantitative analysis of herpes simplex virus DNA and transcriptional activity in ganglia of mice latently infected with wild-type and thymidine kinase-deficient viral strains. J. Gen. Virol. 75:1994;2469-2474.
49. Speck P.G., Simmons A. Divergent molecular pathways of productive and latent infection with a virulent strain of herpes simplex virus type 1. J. Virol. 65:1991;4001-4005.
50. Speck P.G., Simmons A. Synchronous appearance of antigen-positive and latently infected neurons in spinal ganglia of mice infected with a virulent strain of herpes simplex virus. J. Gen. Virol. 73:1992;1281-1285.
51. Steiner I., Kennedy P.G.E. Herpes simplex virus latent infection in the nervous system. J. Neurovirol. 1:1995;19-29.
52. Steiner I., Spivack J.G., Lirette R.P., Brown S.M., MacLean A.R., Subak-Sharpe J.H., Fraser N.W. Herpes simplex virus type 1 latency-associated transcripts are evidently not essential for latent infection. EMBO J. 8:1989;505-511.
53. Stevens J.G., Cook M.L. Latent herpes simplex virus n spinal ganglia of mice. Science. 173:1971;843-845.
54. Stevens J.G., Wagner E.K., Devi-Rao G.B., Feldman L.T. RNA complementary to a herpes simplex virus alpha gene mRNA is prominent in latently infected neurons. Science. 235:1987;1056-1059.
55. Sutton D., Kingsley S.D., Well G.I., Bartus H.R., Esser K.M. Famciclovir treatment of acute herpes simplex virus infection in mice reduces the subsequent frequency of latent virus reactivation induced by transitory hyperthermia. In; Proceedings of 11th International Conference on Antiviral Chemotherapy, San Diego. Antiviral Res : A78 (abstract). 37:1998;135.
56. Tenser R.B. The role of herpes simplex virus thymidine kinase expression in viral pathogenesis and latency. Intervirology. 32:1991;76-92.
57. Thackray A.M., Field H.J. Differential effects of famciclovir and valaciclovir on the pathogenesis of herpes simplex virus in a murine infection model including reactivation from latency. J. Infect. Dis. 173:1996;291-299.
58. Thackray A.M., Field H.J. Comparison of effects of famciclovir and valaciclovir on pathogenesis of herpes simplex virus type 2 in a murine infection model. Antimicrob. Agents Chemother. 40:1996;846-851.
59. Thackray A.M., Field H.J. Famciclovir and valaciclovir differ in the prevention of HSV-1 latency in mice: a quantitative study. Antimicrob. Agents Chemother. 42:1998;1555-1562.
60. Thompson R.L., Sawtell N.M. The herpes simplex virus type 1 latency-associated transcript gene regulates the establishment of latency. J. Virol. 71:1997;5440-5450.
61. Wald A., Benedetti J.K., Davis G., Remington M., Winter C.A., Corey L. A randomized, double-blind, comparative trial comparing high- and standard-dose oral acyclovir for first-episode genital herpes infections. Antimicrob. Agents Chemother. 38:1994;174-176.
62. Watkins A.M., Dunford P.J., Moffatt A.M. et al. Inhibition of virus-encoded thymidine kinase supresses herpes simplex virus replication in vitro and in vivo. Antivir. Chem. Chemother. 9:1998;9-18.
63. Whitley R.J. Herpes simplex viruses. Fields B.N., Knipe D.M., Howley P.M. et al. Fields Virology. 1996;Lippincott-Raven Publishers, Philadelphia.